BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at HSBC Holdings plc from $97.00 to $136.00. They now have a "buy" rating on the stock.
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $145.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its price target lowered by analysts at Morgan Stanley from $145.00 to $139.00. They now have an "overweight" rating on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.44 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at BMO Capital Markets from $130.00 to $143.00. They now have an "outperform" rating on the stock.MarketBeat
- BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateGlobeNewswire
BNTX
Earnings
- 3/10/25 - Beat
BNTX
Sec Filings
- 3/10/25 - Form 20-F
- 3/10/25 - Form 6-K
- 3/4/25 - Form 6-K
- BNTX's page on the SEC website